Episode 310: 309. Hospital-Associated Venous Thromboembolism Prophylaxis Use by Risk Assessment
https://shmpublications.onlinelibrary.wiley.com/doi/abs/10.1002/jhm.13350Xu J et al. Hospital-associated venous thromboembolism prophylaxis use by risk assessment at a large integrated health care net...
28 Kesä 20248min
Episode 309: 308. Mailed feedback to Primary Care Physicians on Antibiotic Prescribing
https://www.bmj.com/content/385/bmj-2024-079329Overprescription of antibiotics by primary care clinicians is a major modifiable driver of antibiotic resistance. Evidence suggests that peer-comparison ...
27 Kesä 20247min
Episode 308: 307. Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES)
Kityo C et al. Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): Week 48 results from a randomised, multicentre, open-label, non-inferio...
25 Kesä 20245min
Episode 307: 306. METHODS MONDAY! What is the 95% Confidence Interval?
95% CI does NOT mean there is a 95% chance the true value is in the interval. It means that if you continually resample, 95% of your confidence intervals (which will vary every time you resample), wil...
24 Kesä 20248min
Episode 306: 305. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline
https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae290/7685305?login=trueChildren aged 1-18 years to prevent rickets and to potentially lower the risk for respiratory tract infection...
21 Kesä 202414min
Episode 305: 304. METHODS MONDAY- What is Power?
What is the power of a study—what is the power calculation? Often say it is the number of people in a study. Power is the probably to correctly reject the null hypothesis. Said differently power is th...
17 Kesä 202415min
Episode 304: 303. Associations Between Surrogate Markers and Clinical Outcomes
Question What is the strength of association between surrogate markers used as primary end points in clinical trials to support Food and Drug Administration (FDA) approval of drugs treating nononcolo...
14 Kesä 20245min
Episode 303: 302. Effects of statin therapy on diagnoses of new-onset diabetes
The incidence of new-onset diabetes was basically the same but statistically significantly higher for those individuals on low-to-moderate–intensity statins compared with placebo 1.2 vs 1.3% annually ...
13 Kesä 20246min
